Accepted answer
Your licensure, not theirs: the prescriber must hold a licence in the state where you are physically located at the time of the encounter. And no, video is not federally required for this drug class — which is precisely why both of the intakes you describe can be lawful in the same country while being wildly different in quality.
The legal skeleton
- Location of the patient governs. Practising medicine happens where the patient is. A prescriber in one state treating you in another needs licensure in yours, or an interstate pathway such as the medical licensure compact, or a state-specific telehealth registration. This is the single most common compliance failure at low-cost platforms, and it is checkable: ask which state the prescriber is licensed in and verify it against your state's board.
- No federal in-person exam requirement here. The federal rule people half-remember applies to controlled substances. GLP-1 receptor agonists are not controlled substances, so that framework simply does not attach, and there is no federal mandate for a video visit or a physical examination before prescribing them.
- State law fills the gap, and it varies sharply. Some states permit asynchronous store-and-forward encounters to establish a relationship. Others require a real-time interactive encounter, at minimum audio, for a first prescription. A meaningful number have statutes stating that a questionnaire alone does not establish a prescriber-patient relationship and that prescribing on that basis is unprofessional conduct. Your four-minute form is lawful in some states and a board complaint in others, on identical facts.
- Standard of care applies regardless of modality. This is the part that does the real work. Telehealth statutes almost universally say the standard of care is the same as in person. So even where an asynchronous intake is permitted as a modality, the content of the assessment still has to meet the standard, and a form that omits height does not.
The defensible minimum
Here is what a competent intake covers and why each item is there. Judge your two services against this rather than against each other.
| Item | Why it is asked | Consequence of skipping it |
|---|
| Height and weight, ideally verified | BMI is the entry criterion for every guideline and every payer policy | No indication can be established at all |
| Personal or family history of medullary thyroid carcinoma or MEN2 | Labelled contraindication for this class | Prescribing against an absolute contraindication |
| History of pancreatitis | Labelled caution; recurrence risk informs the decision | A known-risk patient started without discussion |
| Gallbladder history and current symptoms | Gallbladder events are an established class signal, and rapid weight loss is itself a risk factor | An avoidable acute presentation attributed to nothing |
| Gastroparesis or significant GI motility disorder | The mechanism includes delayed gastric emptying; this compounds it | Severe, sometimes protracted GI toxicity |
| Diabetic retinopathy status, where diabetes is present | A retinopathy-complication imbalance appeared in a cardiovascular outcomes trial in T2DM [1] | Rapid glycaemic improvement in unassessed proliferative disease |
| Current insulin or sulfonylurea | Hypoglycaemia risk requires those doses to be reviewed at initiation | The single most predictable serious adverse event in this class |
| Pregnancy, breastfeeding, contraception, pregnancy plans | Not recommended in pregnancy; effective contraception matters, and this class can affect the absorption context of oral agents | An exposure nobody intended |
| Eating-disorder screening | An appetite-suppressing drug is a specific hazard in restrictive pathology | Iatrogenic harm in exactly the population most likely to seek it |
| Baseline labs: A1c, renal and hepatic panel, lipids | Establishes indication, baselines the monitoring, and finds the undiagnosed diabetes that changes the plan | No way to interpret anything later |
| Written titration plan and a named follow-up | Dose escalation is scheduled and tolerability-dependent, not automatic | Escalation through a nausea signal that should have paused it |
| An adverse-event contact route | Someone has to answer at week three | The emergency department becomes the follow-up plan |
| Consent specific to a compounded preparation, if applicable | It is not an approved product and that fact is material | Consent that was never informed |
Nothing in that list is exotic; it is the labelled cautions plus the obvious monitoring. Note how much of it your first service did and your second did not.
Why the difference exists commercially
Because the assessment is the cost. A forty-minute encounter with a licensed clinician who reads labs is expensive and does not scale; a form that a template approves is nearly free. Where the platform also sells the product, the assessment is a cost centre sitting in front of a revenue event, and the pressure runs one way. That is not an accusation against any particular business, it is a description of the incentive, and it is why the intake is the most informative thing you will ever see about a telehealth service.
One more practical point: the GI adverse-event rate in this class is high enough that the follow-up plan is not a formality. In the pivotal semaglutide obesity trial, nausea was reported by roughly 44% on active drug against 17% on placebo, with adverse-event discontinuations around 7% [2], and those were supervised participants on a defined titration with study staff to call. A service with no contact route is planning for the version of this where nobody calls anyone. Whatever you decide, decide it with a clinician you can reach.
edited 10 Nov 2024 by low_dead_space — removed a claim I could not source
8Standard of care applies regardless of modality is the sentence that resolves the apparent contradiction. Async is allowed; bad is not. – halvard_ness 7 months ago 7The insulin and sulfonylurea row is the one I would move to the top. It is the most predictable serious harm. – mira_sundqvist 6 months ago My intake missed the eating-disorder screen entirely and I flagged it. They added it to the form a month later. – Dr_Bram_Verhoeven 4 months ago add a comment